A Real-World Study of Bispecific Antibodies in Multiple Myeloma

Conditions

• Multiple Myeloma

Interventions

• OTHER: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
• OTHER: Not treated by bispecific antibodies in usual care

Sponsor

Assistance Publique - Hôpitaux de Paris